Kyntra Bio Inc (NASDAQ:KYNB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $30.00.

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Kyntra Bio in a research report on Tuesday, June 16th. Wall Street Zen upgraded Kyntra Bio from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Oppenheimer initiated coverage on Kyntra Bio in a report on Monday. They issued an “outperform” rating for the company. Finally, Rodman & Renshaw started coverage on Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price for the company.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC acquired a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned approximately 0.68% of Kyntra Bio as of its most recent filing with the SEC. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Kyntra Bio Price Performance

Shares of NASDAQ KYNB traded down $0.38 during trading hours on Monday, hitting $7.25. The company had a trading volume of 19,563 shares, compared to its average volume of 25,571. Kyntra Bio has a 1-year low of $5.37 and a 1-year high of $12.60. The firm’s 50 day moving average price is $7.00. The stock has a market capitalization of $29.35 million, a PE ratio of 0.18 and a beta of 0.96.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.